Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Biosceptre Posts Positive Results for Basal Cell Carcinoma Drug

By Drug Discovery Trends Editor | July 23, 2014

Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, announced positive results from its Phase 1 trial to assess the safety and tolerability of BIL-010t (formerly known as BSCT (Anti-nf-P2X7) 10% Ointment), a topically administered, highly purified sheep antibody therapy, to treat Basal Cell Carcinoma (BCC).
 
The Phase 1 trial, conducted in the US, was an open-label, single-arm, multicenter study, to assess safety, tolerability, and levels of anti-drug antibodies in the patients’ serum. The study enrolled 21 male and female patients, with a BCC lesion histologically confirmed within the previous four weeks, who self-applied the BIL-010t ointment for 28 days. 
 
The results showed that BIL-010t was both safe and well tolerated, with very high levels of patient compliance. The only reported side effect, associated with treatment, was mild to moderate localized skin reactions. Levels of BIL-010t were generally undetectable in patients’ blood serum, and gave no evidence of immunogenicity in the majority of patients.
 
Although efficacy was not a prescribed endpoint of the trial, it was noted that 65% of patients (13 out of 20) who completed the study had decreases in the size of their BCC lesions. The reductions ranged from 10% to 56% reduction in the size of the BCC during the course of treatment. 
 
“The results from this trial are extremely encouraging for the potential of nf-P2X7 as an entirely new target to treat cancer,” said Gavin Currie, CEO of Biosceptre. “BIL-010t is our lead topical program for BCC, a form of cancer that results in between two and three million new cases in the US each year. This therapy has the potential in many cases to replace expensive, and often disfiguring, surgery.” 
 
Date: July 23, 2014
Source: Biosceptre

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50